Tarsus Pharmaceuticals (TARS) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

TARS Tarsus Pharmaceuticals

Watchlist

50.220
-2.010-3.85%

Close Feb 14 16:00 ET

50.220
0.0000.00%

Post 16:27 ET

1.92BMarket Cap-13.39P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Express News | Guggenheim Reiterates Buy on Tarsus Pharmaceuticalsto Buy
BenzingaFeb 10 09:20 ET
Investors Appear Satisfied With Tarsus Pharmaceuticals, Inc.'s (NASDAQ:TARS) Prospects
Simply Wall StFeb 7 13:43 ET
Strong Growth Prospects and Market Expansion Drive Buy Rating for Tarsus Pharmaceuticals
TipRanksFeb 4 15:25 ET · Ratings
Breakeven On The Horizon For Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)
Yahoo FinanceFeb 4 08:49 ET
BofA Adjusts Price Target on Tarsus Pharmaceuticals to $75 From $74
MT NewswiresFeb 3 10:35 ET · Ratings
Tarsus to Participate in Upcoming Investor Conferences
GlobeNewswireJan 30 17:00 ET

Comments

Jerry Kronenberg

Nov 13, 2024 15:29

Columns Tarsus Pharmaceuticals Gains Some 15% After Hours on Better-Than-Expected Q3 Results

$Tarsus Pharmaceuticals (TARS.US)$ rose some 15% in after-hours trading Wednesday after the biotech reported a narrower-than-Q3 expected loss and better-than-forecast quarterly revenues.
TARS – which makes XDEMVY, a prescription eye drop to treat optical disease Demodex blepharitis – gained 14.5% to $53.25 shortly before 4:30 p.m. ET after unveiling a $0.61 Q3 loss, beating the $0.92 that analysts had reportedly f...

MMu

Oct 29, 2024 15:16

$Tarsus Pharmaceuticals (TARS.US)$ wonder which 2 pharmas are bidding for Tarsus!!

Stock_Drift

Oct 28, 2024 04:33

Pre Market Ticks. 5:32am 10/28

$Jet.AI (JTAI.US)$ $ProShares UltraShort Bloomberg Crude Oil ETF (SCO.US)$ $Phunware (PHUN.US)$ $ImmunityBio (IBRX.US)$ $Longeveron (LGVN.US)$ $BIOSIG TECHNOLOGIES INC (BSGM.US)$ $Tarsus Pharmaceuticals (TARS.US)$ $XTL Biopharmaceuticals (XTLB.US)$ $LENZ Therapeutics (LENZ.US)$ $TC BioPharm (TCBP.US)$ $Top Wealth Group Holding (TWG.US)$ $Healthcare Triangle (HCTI.US)$ $Pixie Dust Technologies(Delisted) (PXDT.US)$
📊⚡️📊

Jaguar8

Aug 8, 2024 15:17

NEWS

$Tarsus Pharmaceuticals (TARS.US)$
Tarsus Reports Second Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements
Tarsus Pharmaceuticals (NASDAQ: TARS) reported strong Q2 2024 financial results, with XDEMVY® net product sales reaching $40.8 million, a 65% increase from Q1.
Year-to-date sales totaled $65.5 million.
The company delivered over 37,000 bottles to patients in Q2 and achieved an impressive gross-to-net discount of 44%.
Tarsus expanded payer coverage, incl...

Moomoo AI

Mar 1, 2024 12:53

Analysts predict Tarsus Pharmaceuticals' growth to outpace the industry with a 5x annualised growth by 2024. The upgraded price target indicates an expected increase in the business's intrinsic value.